CalciMedica (NASDAQ:CALC) Stock to Reverse Split on Monday, August 31st

Shares of CalciMedica Inc. (NASDAQ:CALC) are scheduled to reverse split before the market opens on Monday, August 31st. The 1-5 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Sunday, August 30th.

CalciMedica Price Performance

CALC traded down $0.12 during trading on Thursday, reaching $0.47. The company’s stock had a trading volume of 1,490,454 shares, compared to its average volume of 1,026,720. The company has a quick ratio of 5.58, a current ratio of 5.58 and a debt-to-equity ratio of 1.67. The firm has a fifty day simple moving average of $0.76 and a two-hundred day simple moving average of $0.70. CalciMedica has a 1 year low of $0.46 and a 1 year high of $7.20. The company has a market cap of $16.05 million, a price-to-earnings ratio of -0.35 and a beta of 0.91.

CalciMedica (NASDAQ:CALC) last posted its quarterly earnings results on Tuesday, August 11th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($0.17). As a group, analysts anticipate that CalciMedica will post -1.05 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on the stock. Wall Street Zen raised shares of CalciMedica to a “sell” rating in a research note on Saturday, August 22nd. Guggenheim assumed coverage on CalciMedica in a research report on Thursday, August 20th. They issued a “buy” rating on the stock. HC Wainwright reissued a “neutral” rating on shares of CalciMedica in a research report on Wednesday, July 29th. UBS Group restated a “neutral” rating on shares of CalciMedica in a research note on Thursday, August 13th. Finally, Weiss Ratings lowered CalciMedica from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, August 13th. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, CalciMedica currently has a consensus rating of “Hold” and a consensus target price of $10.00.

Insider Activity at CalciMedica

In other CalciMedica news, Director Fred A. Middleton purchased 248,972 shares of the stock in a transaction that occurred on Thursday, June 25th. The stock was purchased at an average cost of $0.80 per share, with a total value of $199,177.60. Following the completion of the acquisition, the director directly owned 1,063,272 shares of the company’s stock, valued at $850,617.60. This trade represents a 30.57% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 28.25% of the company’s stock.

Hedge Funds Weigh In On CalciMedica

Institutional investors have recently added to or reduced their stakes in the stock. Cetera Investment Advisers raised its holdings in CalciMedica by 33.1% during the second quarter. Cetera Investment Advisers now owns 36,385 shares of the company’s stock worth $58,000 after purchasing an additional 9,045 shares in the last quarter. 180 Wealth Advisors LLC raised its position in CalciMedica by 297.2% during the first quarter. 180 Wealth Advisors LLC now owns 126,500 shares of the company’s stock worth $68,000 after acquiring an additional 94,650 shares during the last quarter. Renaissance Technologies LLC lifted its stake in CalciMedica by 45.0% in the 1st quarter. Renaissance Technologies LLC now owns 128,075 shares of the company’s stock valued at $69,000 after buying an additional 39,775 shares in the last quarter. Jane Street Group LLC acquired a new stake in shares of CalciMedica during the fourth quarter valued at $127,000. Finally, Envestnet Asset Management Inc. grew its holdings in shares of CalciMedica by 58.2% during the second quarter. Envestnet Asset Management Inc. now owns 93,433 shares of the company’s stock worth $149,000 after buying an additional 34,386 shares in the last quarter.

About CalciMedica

CalciMedica, Inc (NASDAQ:CALC) is a clinical-stage biopharmaceutical company focused on developing therapies that modulate calcium-mediated inflammatory pathways. Headquartered in Northbrook, Illinois, the company applies proprietary ion channel technology to address severe inflammatory disorders driven by dysregulated immune responses.

The company’s lead product candidate, Auxora™, is a selective inhibitor of calcium release-activated calcium (CRAC) channels. Auxora is being evaluated in clinical trials for the treatment of acute pancreatitis associated with systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome (ARDS) in patients with severe pulmonary conditions, including COVID-19 pneumonia.